Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRAIL Inc

Data Support Clinical Performance of Galleri   to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

DaVita

Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.

2 Must-Buy Medical Stocks With Strong Momentum

TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances access to localized precision oncology for patients SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 2024 results showed a gross margin of 68% and a net loss of $1.988 billion, mainly due to impairments.

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

ILMN has shown bullish signs with price action improving, above 30-week EMA, and potential for trend change. Volume analysis indicates institutional buying, momentum is short-term bullish, and long-term momentum may soon turn bullish. Relative strength has improved since June, suggesting ILMN is outperforming the SP 500 index, making it a potential buy opportunity.

Illumina Looks Bullish (Technical Analysis)

Illumina, Inc. (NASDAQ:ILMN ) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ET Company Participants Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur Dhingra - CFO Conference Call Participants Operator Salli Schwartz Thank you for joining us today. My name is Salli Schwartz and I'm Illumina's Head of Investor Relations.

Illumina, Inc. (ILMN) Illumina 2024 Strategy Update Special Call

Illumina said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene sequencing using a novel method based on the Nobel Prize-winning CRISPR technology.

Illumina, CRISPR-pioneer Broad Institute to work on new gene sequencing kits

-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics -- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost -- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027 -- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today is hosting a Strategy Update for investors to present its strategy and three-year financial outlook that features accelerating revenue growth and significant margin expansion. "Illumina built the foundation of the genomics industry, and we will continue leading innovation across total sequencing workflows to support the next phase of our customers' success," said Jacob Thaysen, Chief Executive Officer of Illumina.

Illumina announces strategy to accelerate value creation

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Understanding Illumina (ILMN) Reliance on International Revenue

Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

Illumina, Inc. (NASDAQ:ILMN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Conor McNamara - RBC Capital Markets Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Dan Arias - Stifel Tycho Peterson - Jefferies Subha Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research David Westenberg - Piper Sandler Dan Brennan - TD Cowen Operator Good day ladies and gentlemen and welcome to the Second Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.

Illumina, Inc. (ILMN) Q2 2024 Earnings Call Transcript

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics

Illumina (ILMN) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.32 per share a year ago.

Illumina (ILMN) Q2 Earnings and Revenues Top Estimates

Gene sequencing machine maker Illumina on Tuesday forecast 2024 sales from its core segment to decline, a sign that subdued demand for its instruments used in genetic tests could extend further into the year.

Illumina expects full-year sales from core segment to decline on biotech funding crunch

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024 Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023 Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024 Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024 On June 24, 2024, we completed the spin-off of GRAIL into a new public company SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2024, which include the consolidated financial results for GRAIL through June 24, 2024. "The Illumina team delivered results ahead of our expectations in the quarter, driven by disciplined execution on our strategic priorities," said Jacob Thaysen, Chief Executive Officer.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeq™ X Series customers. The company began offering the newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months.

Illumina launches new oncology menu for NovaSeq X Series customers

Genmab - ADR

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Stay Ahead of the Game With Illumina (ILMN) Q2 Earnings: Wall Street's Insights on Key Metrics

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Illumina (ILMN) Could Beat Earnings Estimates Again

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

Adaptive Biotechnologies

Guardant Health Inc

Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.

News for Illumina Stock (ILMN)